Oncolytics posts positive colo-rectal cancer preclinical results
The company reported that combining its drug pelareorep with a RAS inhibitor maintained anticancer activity, supporting clinical investigation to combat therapy resistance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day